ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Business Activity | PASS |
| Debt Ratio (0.39%) | FAIL |
| Cash Ratio (0.05%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-05-25 | 3.12 | Pending | — |
| 2025-10-22 | 3.28 | 3.31 | +1.0% |
| 2025-07-23 | 3.18 | 3.26 | +2.4% |
| 2025-04-30 | 3.09 | 3.19 | +3.1% |
| 2025-02-19 | 3.43 | 3.43 | +0.1% |
| 2024-10-23 | 3.85 | 3.35 | -13.1% |
| 2024-07-24 | 3.67 | 3.75 | +2.1% |
| 2024-04-24 | 3.41 | 3.47 | +1.7% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2025-09-30 | $2.0B | $2.4M | $186.8M | $554.4M | $258.9M | 0.03 |
| 2025-06-30 | $2.0B | $183.0M | $309.0M | $561.6M | $258.9M | 2.31 |
| 2025-03-31 | $2.0B | $154.2M | $317.3M | $558.7M | $264.3M | 1.91 |
| 2024-12-31 | $2.0B | $260.0M | $365.6M | $599.4M | $351.3M | 3.18 |
| 2024-09-30 | $2.0B | $197.1M | $380.9M | $591.4M | $293.3M | 2.38 |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Artisan Partners Limited Partnership | 8.3M | $966.8M | 0.1% |
| Wellington Management Group, LLP | 5.9M | $690.5M | 0.1% |
| Harris Associates L.P. | 4.4M | $508.1M | 0.1% |
| FMR, LLC | 4.2M | $487.4M | 0.1% |
| Invesco Ltd. | 3.9M | $453.0M | 0.0% |
| Principal Financial Group, Inc. | 3.3M | $386.7M | 0.0% |
| Brave Warrior Advisors, LLC | 3.0M | $350.0M | 0.0% |
| Massachusetts Financial Services Co. | 2.7M | $318.6M | 0.0% |
| Sachem Head Capital Management, LP | 2.1M | $245.8M | 0.0% |
| Greenhaven Associates, Inc. | 2.0M | $233.8M | 0.0% |
Buy
Hold
Sell
Strong Sell
$12.0B
0.96
1.227
14
$8.1B
$3.6B
-98.7%
2.12
2.02
0.0%
39,800
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-05-25 | $3.12 | Pending | — |
| 2025-10-22 | $3.28 | $3.31 | +1.0% |
| 2025-07-23 | $3.18 | $3.26 | +2.4% |
| 2025-04-30 | $3.09 | $3.19 | +3.1% |
| 2025-02-19 | $3.43 | $3.43 | +0.1% |
| 2024-10-23 | $3.85 | $3.35 | -13.1% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($132.60, 15 analysts) | |||
| 10 | $1,173.80 | +$152.20 (13%) | 0.9R |
| 50 | $5,869.00 | +$761.00 (13%) | 0.9R |
| 100 | $11,738.00 | +$1,522.00 (13%) | 0.9R |
| To Fair Value ($172.02) | |||
| 10 | $1,173.80 | +$546.40 (47%) | 3.1R |
| 50 | $5,869.00 | +$2,732.00 (47%) | 3.1R |
| 100 | $11,738.00 | +$5,464.00 (47%) | 3.1R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| IQV | 0.610 |
| TMO | 0.502 |
| CRL | 0.479 |
| RVTY | 0.470 |
| BRKR | 0.444 |
| Ticker | Correlation |
|---|---|
| MGRT | -0.337 |
| SDR.L | -0.283 |
| 6326.T | -0.226 |
| BN.PA | -0.187 |
| 4292.SR | -0.173 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500